Injection Devices
EyePoint Pharmaceuticals Announces $15.7-Million Equity Investment
EyePoint Pharmaceuticals, Inc. recently announced Ocumension Therapeutics has made a $15.7-million equity investment in EyePoint. Under the terms of the agreement, Ocumension has purchased approximately…
Vectura Earns $11-Million Milestone as Hikma Receives US FDA Approval for Generic Advair DiskusR
Vectura Group plc recently announced its partner Hikma Pharmaceuticals has launched its generic version of GlaxoSmithKline’s Advair Diskus (fluticasone propionate and salmeterol inhalation powder)….
New Clinical Trial Data Demonstrates BD Libertas Wearable Injector as a Drug Delivery System
BD (Becton, Dickinson and Company) recently announced publication of the results from a 52-subject human clinical trial with the BD Libertas Wearable Injector…..
BD to Invest $1.2 Billion in Pre-Fillable Syringe Manufacturing Capacity
BD (Becton, Dickinson and Company), a leading global medical technology company, recently announced plans to invest approximately $1.2 billion over a 4-year period to expand and upgrade manufacturing capacity….
Kindeva & BOL Pharma Sign Agreement for Development of Inhaled Cannabinoid Products
Kindeva Drug Delivery and Breath of Life International recently signed an agreement to study the feasibility of multiple inhaled cannabinoid products…..
Bormioli Pharma Acquires ISO GmbH
Bormioli Pharma recently announced the acquisition of ISO Arzneiverpackungen Gmbh, a German company specialized in the production of pharmaceutical packaging and, in particular, of tubular…
Baxter Biopharma Solutions Announces $50-Million Investment
Baxter International Inc. recently announced a $50-million expansion of its sterile fill/finish manufacturing facilities located in Bloomington, IN. These facilities are operated by Baxter’s BioPharma…
Foster Corporation Enters Marketing Partnership With Aran Biomedical
Foster Corporation recently announce a new business relationship with Aran Biomedical, a global leader in biomaterial product solutions for implantable medical devices…..
Recipharm Announces Signature of Letter of Intent for Aseptic Fill-Finish Manufacturing of Moderna’s COVID-19 Vaccine Candidate
Recipharm, a leading contract development and manufacturing organization (CDMO), recently announced that it has signed a letter of intent with Moderna, a US-based biotech company, to formulate, fill, and….
2021 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
POLYMERIC DELIVERY SYSTEM - Next-Generation Long-Acting Implantables Using Surface-Eroding Elastomers
Stephanie Reed, PhD, Carissa Smoot, and Dennis Shull describe how PGSU ultimately offers many advantages over other polymers for long-acting implantables, particularly for high-loading, long-duration implants that are gaining interest in the pharmaceutical industry.
Evaluation Kit for Sensirion’s Single-Use Liquid Flow Sensor LD20-2600B is Now Available for Distribution
The LD20-2600B single-use liquid flow sensor for fast, precise and reliable measurements of the lowest flow rates in biomedical applications was successfully launched….
Atossa Therapeutics Announces Preliminary Results from Phase 1 Clinical Study of Nasal Spray Being Developed for COVID-19
Atossa Therapeutics, Inc. recently announced blinded preliminary results from its Phase 1 clinical study using Atossa’s proprietary drug candidate AT-301 administered by nasal spray. AT-301…
Halberd Corporation Files for Patent Protection on Enhanced Nasal Spray to Prevent Covid-19
Halberd Corporation reported the filing of a Covid-19 provisional patent on an enhanced nasal spray. The application, Nasal Spray to Prevent the Transmission of Covid-19,…
Aerogen Collaborates on Development of More Than 15 Potential COVID-19 Inhaled Therapies
Aerogen recently announced details of a broad collaborative effort to support pharmaceutical companies from around the world as they work to develop COVID-19 vaccines and…
Nemera to Acquire Copernicus to Boost Parenteral Product Portfolio & Small Series Capabilities
Nemera recently announced it has entered into an agreement to acquire Copernicus, which specializes in the development and manufacturing of injection devices…
WEBINAR SERIES ALERT - Learn About Complex Parenteral Drug Delivery From Evonik Industry Experts - Free Oct-Nov Webinar Series
As a global CDMO leader for advanced drug delivery, Evonik invites you to join us for a webinar series on parenteral drug delivery. More than a dozen technical experts from Evonik will review….
Scientific Management of Pharmaceutical Container Closure & Delivery Device Compatibility
Diane Paskiet says the relationship between pharmaceutical products and CC/DD is best managed through a rich science-based approach that factors in potential risk and is adapted early in the development process.
Noble & Aptar Pharma Connected Medical Device Solution for Disease Management Adherence & Onboarding Patients
Noble and Aptar Pharma recently announced the launch of AdhereIT - a connected, intuitive, and user-friendly onboarding solution for the growing number of patients with…
Gerresheimer Includes Stevanato Group Integrated Twist-Off Closure System Solution for Gx RTF Syringes
Gerresheimer will offer its Gx RTF syringes with SG ITC (Integrated Tip Cap) twist-off closure of the Stevanato Group. With this technology, which is often…
What are Injection Devices?
Drug delivery devices are the physical agents that are included in the drug delivery system. There are a multitude of devices that people interact with every day which fall under this category. In modern pharmaceuticals, novel drug delivery devices and combination products are being designed for a number of reasons, including giving patients the ability to self-administer some medications at home, which can help them adhere to recommended regimens.
Evolution of Injection Devices
With modern technology and medicine, the combination product market is evolving. Any combination device, especially drug device combination devices, must follow strict guidelines. Thanks to advancements in engineering, an increasing number of drug delivery devices are being developed as electromechanical devices linked to apps in order to provide patients with more supervision when administering medications at home. Some of these medical apps may receive feedback from the device to track how much drug is being administered and how often, provide patients with dosing reminders and connect clinicians with this information so they can monitor patient compliance. The drug delivery devices that so many patients depend on must adhere to regulatory standards. There are strict guidelines for all methods of drug delivery, such as needle-based, aerosol, and needle-free injectors.
Smart devices, interconnectivity, and related technology provide real-time data to healthcare providers for analysis, but these device additions should not increase risks, including patient understanding of treatment delivery, or jeopardize compliance. Data collection needs to be “passive” to the patient. In other words, invisible to the patient’s use of the device so that the collected data provides a true benefit to the end user. If these design considerations can be implemented without impacting the patient or how they administer and receive treatment, then smart devices can provide advantages to the patient and the industry.
Injection Device Global Market Trends
The global injectable drug delivery devices market is expected to show significant growth in the coming years as manufacturers introduce technological advancements and product innovation meant to improve convenience, compliance, and ease of administration of parenterals. Additionally, the increasing preference for at-home self-injection is driving the market as patients prefer to continue to avoid healthcare settings post-COVID. With all of this taken into account, one market study predicts the global market to reach almost $26 billion by 2025, up from $15 billion in 2020. However, another report values the global market at $42.76 billion in 2021 and expects it to reach $50.9 billion in 2025.
How the numbers will play out is yet to be determined, but the studies do highlight the focus on single-use and reusable systems. Disposable-use prefilled syringes (PFS) are increasingly used due to the prevalence of chronic diseases and the growing number of biologics best delivered by syringes. Single-use autoinjectors are also poised to experience increased demand, particularly with the growing pervasiveness of anaphylaxis disorders. Autoinjectors also provide a convenient alternative to manual syringe injections for subcutaneous administration.
Reusable Injection Devices
Pen injectors with prefilled cartridges have also proven to be a viable alternative to syringes. These injectors can perform hundreds of injections, with patients controlling the speed of delivery to minimize pain or discomfort during use.
Making injection devices partially reusable is a cost-saving strategy. Ideally, the device’s mechanism and/or electronics are the reusable parts of the system – as these are often the costliest – and the drug containers and needle are one-time use.
Another cost-saving strategy that several large pharmaceutical companies are deploying is to develop a device platform for multiple drug products in their portfolio. This allows them to spend resources on a single significant development program, for one optimal injection device, which then requires minimal customization for each sub-sequent product line.
Despite efforts to make better, safer, simpler injection devices, patient adherence is still a challenge associated with self-administration. This has resulted in the emergence of smart devices, such as wearable injectors, which share patient data with healthcare providers to ensure compliance. And while it is expected this sector will continue to grow, some industry insiders warn against making these devices too intrusive.